SUPPLEMENTARY

MANIKGAD – IV: SUMMER- 2017 SUBJECT: PHARMACOTHERAPEUTICS - III

| | | | | | I': PHARMAC | | | | | |
|------|----------------------|----------------------------|---|---|--|---|--------------------------|---------------------------|----------|--------------|
| Day | : | Mc | onde | 2017 | | 3 | Time : 2 | 2:00 P.M. | To 5. | 00 P.I |
| Date | | 03 | -07. | 2017 | | | Max. M | arks: 70 | | |
| N.B. | 2 3 4 |)) | TWO Answe Draw | questions for the questions for the questions of the question | o.5 are COMPU from each section the sections should diagram WHE that indicate FUL | n. ıld be writte REVER ne | n in SE l | PARATE ans | | |
| | | | | | SECTI | ON – I | | | | |
| Q.1 | A) | Att i) ii) iii) iv) v) vi) | Ment Diffe Class What What | ion classic rentiate bet sify hepatiti are the adv | of the following sign and sympto ween Ischemic as. The series of one effects of Benzrug regimen used | ms of migra and hemorrhapioid analge codiazepines | agic stro esics? ? | | | [08] |
| | B) | • | | | gorithm for Infla | • | | | | [03] |
| Q.2 | -, | Des | cribe t | | ysiology, clinica | | | | erapy of | [12] |
| Q.3 | a) | | | oout etiopatiency Anem | thogenesis, treat | ment object | tive and | pharmacothe | erapy of | [07] |
| | b) | | | | oke and its man | agement. | | | | [05] |
| Q.4 | a) b) c) d) | Dru The Dru | g induc rapeuti g induc | ed hemolyt c drug mon | itoring of Antier sis jaundice | | ng: | | | [12] |
| | | | | | SECTIO | N – II | | | | |
| Q.5 | A) | i) ii) iii) iv) v) vi) | Define Menti Enlist What source What | e Ascitis. on in brief the adverse is the role es of folic a do you und do you und | erstand by Tensi erstand by Bipol | ical manage sychotics. in megalob on type head ar disorder? | lastic ar | | ion few | [08] |
| | B) | Prov | ride a tr | eatment alg | gorithm for the H | I. <i>Pylori</i> infe | ction. | | | [03] |
| Q.6 | | man | agemer | nt. | seizures, their | | | | oyed in | [12] |
| - | a) b) | Defi | ne affe | ctive disord | sis and treatment er and discuss th | e managem | ent of A | isease. ffective disor | | [07] [05] |
| | a) b) c) d) | Opio PICO Drug | oid anal O Analy o therap | gesics | NY THREE of and an | the following | g: | | | [12] |

SUPPLEMENTARY

SUMMER- 2017 MANIKGAD – IV: SUBJECT: CLINICAL PHARMACY

Time: 2:00 P.M. To 500 Day: Wednesdar PM Max. Marks: 70 Date: 05.07.2017 N.B.: Q. No. 1 and Q. No. 5 are COMPULSORY. Out of the remaining attempt any 1) TWO questions from each section. Figures to the right indicate FULL marks. 2) Answers to both the sections should be written in SEPARATE answer books. 3) **SECTION-I** (08)Q.1 A) Answer any FOUR out of SIX: Define Pharmacovigilance. i) Expand following abbreviations SGPT and MCHC. What is Patient history interview? iii) iv) What is the significance of BUN? Define medical ward rounds. v) Define Drug Utilization Evaluation. (03)B) What are augmented adverse drug reactions? Give examples. What is drug information service? Discuss various advantages and (12)Q.2 disadvantages of different resources. Enlist different liver function tests. Explain tests that signify hepatic injury. (07)Q.3 (05)Discuss medication order review. (12)Answer any THREE of the following: Q.4 Management of Adverse Drug Reactions. b) Pharmacist Intervention. Therapeutic drug monitoring. c) d) Clinical Review Patient counseling aids SECTION-II (08)Answer any FOUR out of SIX: Q.5 A) i) Expand FEV and LDH. ii) What is tidal volume? iii) What is hyperkalemia? iv) Give significance of serum calcium. What is MBC? Give its significance. vi) What are aims of Pharmacovigilance? (03)B) How will you report adverse drug reaction? What is Poison information service? Discuss the approach for answering (12) Q.6 Poison information query. Discuss various scales used for causality assessment of Adverse Drug (07) Q.7 a)Reactions. (05)Explain the setup of a drug information Centre. (12)Answer any THREE: 0.8 a) Nonverbal communication skills b) Poison information resources.

c) Lung flow tests Cardiac enzymes

e) Hyponatremia

d)

SUPPLEMENTARY

MANIKGAD – IV: SUMMER- 2017

SUBJECT: BIOSTATISTICS & RESEARCH METHODOLOGY

Day : Thursday Date : 06-07.2017

Time: 2:00 P.M. TO 5:00 P.M.

Max. Marks: 70

N.B.:

- Q.No.1 and Q.No.5 are COMPULSORY. Out of the remaining questions attempt ANY TWO questions from each section.
- 2) Answers to both the sections should be written in the SEPARATE answer books.
- 3) Statistical tables and graph papers will be supplied at the examination centre.
- 4) Use of non-programmable electronic pocket calculator is ALLOWED.
- 5) Figures to the right indicate FULL marks.

SECTION - I

Q.1 A) Answer ANY FOUR of the following:

[08]

- i) Explain the term 'Hypothesis'.
- ii) What do you understand by the term 'Research Design'?
- iii) State any one modification introduced to avoid bias in the 'Intervention study'
- iv) Indicate one important application of computers in community pharmacy.
- v) Give the long form of MEDLARS.
- vi) What is the advantages of using the Alpha-Numeric codes instead of Numeric Codes?
- B) Differentiate between Parallel Experimental Design and Cross-over [03] Experimental Design.
- Q.2 What do you understand by the term 'Interventional Studies'? Discuss the various modifications introduced to avoid any bias in the 'Interventional Studies'.
- Q.3 Describe in details the role of computers in the Hospital Pharmacy indicating [12] in details the various systems used.
- Q.4 Describe the procedure for determining the sample size while estimating the [12] mean using the confidence level approach.

SECTION - II

Q.5 A) Answer ANY FOUR of the following:

[08]

- i) Give one example of the continuous variable.
- ii) Write the minimum and the maximum value of the Probability.
- iii) Give the maximum value of Karl Pearson's Correlation coefficient.
- iv) Compute the median and mode for the following: 23, 43, 17, 43, 58, 62, 45.
- v) Give one example of Poisson Distribution.
- vi) Explain the term 'Standard Probability Distribution'.
- B) Explain in details the terms Incidence and Prevalence.

[03]

P.T.O.

Q.6 a) Draw the 'Less than Ogive' curve for the following data:

[07]

| | | | | | 20 25 | 25 40 |
|--------------------|---------|---------|---------|---------|---------|---------|
| Age of the patient | 10 - 15 | 15 - 20 | 20 – 25 | 25 - 30 | 30 - 35 | 35 – 40 |
| | - | _ | 22 | 16 | Q | 1 2 1 |
| No. of patients | 3 | 9 | 23 | 10 | 0 | |

Using the graph find the approximate value of the Median.

b) The data gives the diastolic B.P. of two patients during a week.

[05]

| Α | 120 | 125 | 123 | 119 | 109 | 126 | 130 |
|---|-----|-----|-----|-----|-----|-----|-----|
| B | 130 | 113 | 127 | 128 | 119 | 117 | 126 |

Find the Coefficient of Variations and decide the patient having consistent B.P.

Q.7 a) The Hb values for some ladies in Europe and Africa are as below:

[07]

| | | 3 | Hb coun | t gm% | | | |
|--------|------|------|---------|-------|------|------|------|
| Europe | 14.0 | 14.5 | 15.0 | 15.3 | 14.7 | 14.8 | 15.1 |
| Africa | 14.2 | 14.4 | 14.7 | 15.0 | 14.4 | 14.6 | 14.9 |

Use the sign test to test whether the Hb values for the ladies in Europe and in Africa differ significantly. (Use 5% L.O.S).

b) If the average count of RBCs for the healthy men is 5.0 million/mm³. find the probability that the RBC count for a randomly selected healthy man is exactly 6.0 million/mm³.

Q.8 a) Following are the cholesterol values (mg%) for men in different professions: [07]

| Teachers | 160 | 153 | 157 | 159 | 163 |
|---------------|-----|-----|-----|-----|-----|
| Lawvers | 230 | 222 | 228 | 240 | 237 |
| Grain dealers | 180 | 177 | 165 | 173 | 179 |

Draw ANOVA Table and test whether the cholesterol values for the professions differ significantly. (Use 5% L.O.S).

b) The results of using the newly developed drug for curing the Dengue are as below: [05]

| | Drug used | Drug not used (conventional method used) |
|-----------|-----------|--|
| Cured | 80 | 85 |
| Not cured | 25 | 65 |

Determine whether the newly developed drug is effective for curing the disease. (Use 5% L.O.S.)

SUPPLEMENTARY MANIKGAD – IV: SUMMER- 2017 SUBJECT: BIOPHARMACEUTICS & PHARMACOKINETICS

| Day | , | : Friday Time: 2:00 P.M. To | 5.00 P, N |
|------|----------------------|--|------------------|
| Date | е | : 07.07-2017 Max. Marks: 70 | |
| N.B | : | Q.No.1 and Q.No.5 are compulsory. Out of the remaining questions atto ANY TWO questions from each section. Answers to both the sections should be written in the SEPARATE answ Draw neat and labeled diagrams WHEREVER necessary. Figures to the right indicate FULL marks. | |
| | - | SECTION – I | |
| Q.1 | a) | Answer ANY FOUR of the following: i) What is blood brain barrier and placental barrier? ii) What are hydrolytic reactions of biotransformation? iii) What is Fick's first law of diffusion? iv) Write Biopharmaceutical Classification System of drugs with examples. v) What is dialysis and haemoperfusion? | [08] |
| | b) | Write the sequence of events in the absorption of drugs from ora administered solid dosage forms. | lly [03] |
| Q.2 | | Discuss formulation related factors affecting absorption of drugs. | [12] |
| Q.3 | a) | Discuss Phase - I and Phase - II reactions in biotransformation. | [07] |
| | b) | Write the difference between plasma protein-drug binding and tissue-drubinding. | ug [05] |
| | a) b) c) d) | Write short notes on ANY THREE of the following: Enterohepatic cycling Salt form of drug Active transport Barriers to drug distribution | [12] |
| | | SECTION – II | |
| Q.5 | a) | Answer ANY FOUR of the following: i) Define pharmacokinetics and clinical pharmacokinetics. ii) Explain dosage regimen and therapeutic window. iii) What is zero order kinetics? iv) Explain elimination half-life. v) What is nonlinear pharmacokinetics? | [08] |
| 1 | b) | If the plasma concentration of viomycin after i.v. bolus administration wa found to be 10 and 5.5 mcg/ml at 2 and 4 hours respectively, assuming one compartment kinetics. Calculate half life of the drug. | s [03] |
| 2.6 | | Derive the pharmacokinetic parameters for iv bolus administration assuming one compartment open model. | g [12] |
| .7 : | a) | Elaborate on the study designs employed to establish bioequivalence. | [07] |
| | b) | Write the difference between compartment and physiological model. | [05] |
| b | b) c) | Write short notes on ANY THREE of the following: Methods for enhancement of bioavailability In-vitro drug dissolution testing models Sigma minus method Statistical moment theory | [12] |

SUPPLEMENTARY MANIKGAD - IV: SUMMER- 2017 SUBJECT: CLINICAL TOXICOLOGY

Day: Saturday Time: 2.00 PM . To 5.00 Date: 08.07 - 2017 Max Marks. 70 P.M. N.B. 1) Q. No. 1 and Q. No. 5 are COMPULSORY. 2) From the remaining answer any other TWO questions from Section - I and TWO questions from Section - II. 3) Answer Section - I and Section - II on SEPARATE answer books. 4) Figures to the right indicate FULL marks. **SECTION - I** Q.1 Answer any FOUR of the following a) (08)i) Define poison ii) Enumerate types of poisoning Enlist signs and symptoms of opiate poisoning. iii) What is vitriolage? iv) Mention signs and symptoms of ammonia poisoning. v) What are signs and symptoms of radiation toxicity? vi) Describe the signs and symptoms of radiation poisoning. b) (03)Describe the signs and symptoms, treatment, post mortem appearances and (12) Q.2 medico legal aspect of ethyl alcohol poisoning. Q.3 a) Explain the elimination of poison (decontamination). (07)Explain the supportive case in treatment of poisoning. b) (05)Write short notes of THREE of the following. **Q.4** (12)

a)

b)

c) d) **Antidotes**

Hydrochloric acid poisoning Petroleum product toxicity

Paracetamol poisoning

P.T.O.

SECTION - II

| Q.5 | a) | Answer any FOUR of the following | (08) |
|-----|------|--|------|
| | i) | Name four oral iron preparations. | |
| | ii) | Constituents of snake venom | |
| | iii) | Name two poisoning spiders. | |
| | iv) | What are symptoms of scorpion bite? | |
| | v) | What is lathyrism? | |
| | vi) | Enumerate the characteristics of substance abuse. | |
| | b) | What are the signs, symptoms and treatment of bee venom toxicity? | (03) |
| Q.6 | | Describe the signs and symptoms, treatment, post mortem appearance of chronic mercury poisoning. | (12) |
| Q.7 | a) | Define substance abuse. Explain hazards and treatment of tobacco poisoning. | (07) |
| | b) | Describe the mushroom poisoning and its management. | (05) |
| Q.8 | | Write short notes of THREE of the following. | (12) |
| | a) | Antivenin therapy of snake bite | |
| | b) | Aflatoxins | |
| | c) | Copper poisoning | |
| | d) | Botulism | |
| | | | |

(SUPPLEMENTARY)

Supplementing 2017.

MANIKGAD-IV: SUMMER 2017 SUBJECT: PHARMACOTHERAPEUTICS-I + II

Time: 2.00 P. M. TO 5.00 P. M. Max. Marks: 70.

: Monday : 10-07-2017 Date

b)

N.B.:

Q. No. 1 and Q. No. 5 are COMPULSORY. 1)

- Out of the remaining attempt any TWO questions from Section-I and any TWO 2) Questions from Section-II.
- Answers to the two sections should be written in SEPARATE answer books. 3)
- Figures to the RIGHT indicate full marks. 4)

SECTION-I

Attempt any FOUR of the following: O.1 a)

(08)

- Explain JNC-7 guidelines for Hypertension. i)
- Classify Beta-Blockers and give their adverse effects. ii)

Explain Electrophysiological properties of Heart.

- Enumerate various INSULIN preparations. iii)
- Enlist trigger factors of Asthma. iv)
- Give a brief on Oral Contraceptives. v)
- Write down clinical significance of PFT. vi)

(03)

- Q.2 Explain in detail Etiology of Congestive cardiac Failure, clinical presentation, (12) diagnosis and Management of CCF.
- Describe Geriatric Prescribing Guidelines. Q.3 a)

(07)

Role of Pharmacist in Rational Prescribing. b)

(05)

Q.4 Write short notes on THREE of the following:

(12)

- Stepwise management of Asthma a)
- Management of Type-I Diabetes b)
- Pathophysiology and clinical presentation of Myocardial-Infarction c)
- EML and its significance. d)

P.T.O.

SECTION-II

| | | SECTION | (08) |
|------------|---------------------------|--|------|
| Q.5 | a) i) ii) iii) iv) v) vi) | Attempt any FOUR of the following: List factors causing atopic eczema Name two drugs causing psoriasis form eruptions. Enlist factors which exacerbate chronic renal failure. Classify acute renal failure with its characteristics. Name two drugs causing systemic lupus erythematosus. Surgical prophylaxis with antibiotics. Name three drug-interactions of antifungal agents with other drugs indicating | (08) |
| | b) | consequences. | |
| Q.6 | Descr | ribe infections of lower respiratory tract with special reference to COAD and monia. | (12) |
| | | in the of cancer therapy. | (07) |
| Q.7 | a) | Explain basic principles of cancer therapy. | (05) |
| | b) | Comment on drug induced renal disorders with suitable examples. | |
| Q.8 | Write a) b) c) | Psoriasis (Pathophysiology) Viral infections Osteoarthritis | (12) |
| | d) | DOTS Therapy. | |
| | | | |